JAZZ

Jazz Pharmaceuticals' stock price increased by 87.64% over the last 12 months, with a year-to-date return of 41.61% as of September 19, 2026. In Q1 2026, the company reported better-than-expected revenue of $1.07 billion and adjusted EPS of $6.34, reaffirming its full-year guidance, with strong sales growth for Xywav and Epidiolex. Q2 2026 saw total revenues increase by 16% year-over-year, driven by continued strong sales of Xywav, Epidiolex/Epidyolex, Zepzelca, and the inclusion of Modeyso sales. In August 2026, the FDA approved two Ziihera-containing regimens for HER2-positive gastroesophageal adenocarcinoma, which analysts believe opens a significant market opportunity and led to increased price targets. On September 15, 2026, Jazz Pharmaceuticals acquired Actio Biosciences for $820 million. As of September 22, 2026, the stock holds a consensus 'Buy' rating from 18 Wall Street analysts, with an average price target of $286.72, and Goldman Sachs initiated coverage with a 'Buy' rating on September 24, 2026.